(Q28204421)

Journal of Diabetes and its Complications

PubMed

published in

0 references

volume

16

0 references

issue

1

0 references

page(s)

46-9

0 references

cites work

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Angiogenesis inhibitors generated by tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Rb function in cell-cycle regulation and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Endothelial dysfunction in Type 2 diabetic subjects with and without microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

G1 phase progression: cycling on cue

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Expression of cyclin-dependent kinase inhibitors in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900197-0

7 January 2021